A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose escalation study designed to define the maximum tolerable dose(MDT),
the safety profile, pharmacokinetic parameters, immunogenicity and anti-tumor activity of
F0002-ADC in Chinese patients with relapsed/refractory CD30-positive hematologic
malignancies.